AIMC Topic: Canagliflozin

Clear Filters Showing 1 to 3 of 3 articles

Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.

Clinical pharmacology in drug development Dec 11, 2014
Absolute oral bioavailability of canagliflozin was assessed by simultaneous oral administration with intravenous [(14) C]-canagliflozin microdose infusion in nine healthy men. Pharmacokinetics of canagliflozin, [(14) C]-canagliflozin, and total radio...
Humans Young Adult Models, Biological Administration, Oral Area Under Curve Canagliflozin Hepatobiliary Elimination Biological Availability Healthy Volunteers Adolescent Feces Hypoglycemic Agents Infusions, Intravenous Male Adult Middle Aged
View on PubMed DOI

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?

BMJ open diabetes research & care Dec 1, 2019
OBJECTIVE: This study evaluated the characteristics of new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) in clinical practice to assess the applicability of the findings from clinical trials (Empagliflozin, Cardiovascular Outcomes and ...
Aged Middle Aged Retrospective Studies Aged, 80 and over Blood Glucose Female Sodium-Glucose Transporter 2 Inhibitors Bridged Bicyclo Compounds, Heterocyclic Adult Humans Cardiovascular Diseases Observational Studies as Topic Canagliflozin Male Benzhydryl Compounds Glycated Hemoglobin Cohort Studies Clinical Trials as Topic Glucosides Practice Patterns, Physicians' Diabetes Mellitus, Type 2 Diabetic Angiopathies
View on PubMed DOI

Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.

Reviews in cardiovascular medicine Jun 30, 2018
In this systematic review, we sought to summarize the 3 recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials (Dapagliflozin Effect on CardiovasculAR Events (DECLARE-TIMI 58), Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, ...
Benzhydryl Compounds Canagliflozin Glucosides Sodium-Glucose Transporter 2 Inhibitors Sodium-Glucose Transporter 2 Health Status Kidney Diseases Randomized Controlled Trials as Topic Cause of Death Diabetes Mellitus, Type 2 Treatment Outcome Blood Glucose Biomarkers Risk Factors Cardiovascular Diseases Humans Comorbidity Research Design
View on PubMed DOI
Popular Topics
Recent Journals